Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-01-27
DOI
10.1093/oncolo/oyab075
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
- (2021) Elio Adib et al. CLINICAL CANCER RESEARCH
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
- (2020) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- (2020) Vaibhav G. Patel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).
- (2019) Shilpa Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
- (2018) Joaquim Bellmunt et al. BRITISH JOURNAL OF CANCER
- Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
- (2016) Sujata Narayanan et al. Clinical Genitourinary Cancer
- The CAMSAP3-ACF7 Complex Couples Noncentrosomal Microtubules with Actin Filaments to Coordinate Their Dynamics
- (2016) Wenxiu Ning et al. DEVELOPMENTAL CELL
- Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
- (2016) Jaegil Kim et al. NATURE GENETICS
- Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
- (2016) Arlene O. Siefker-Radtke et al. UROLOGY
- The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
- (2015) Zhi Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
- (2015) Günter Niegisch et al. ONCOLOGY
- SAAS-CNV: A Joint Segmentation Approach on Aggregated and Allele Specific Signals for the Identification of Somatic Copy Number Alterations with Next-Generation Sequencing Data
- (2015) Zhongyang Zhang et al. PLoS Computational Biology
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Furry promotes acetylation of microtubules in the mitotic spindle by inhibition of SIRT2 tubulin deacetylase
- (2013) T. Nagai et al. JOURNAL OF CELL SCIENCE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- (2011) Craig H Mermel et al. GENOME BIOLOGY
- Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
- (2010) Satish K. Tickoo et al. BJU INTERNATIONAL
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
- (2009) M Campone et al. BRITISH JOURNAL OF CANCER
- Inactivation of p53 and Pten promotes invasive bladder cancer
- (2009) A. M. Puzio-Kuter et al. GENES & DEVELOPMENT
- Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986
- (2009) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started